Project CBD

APRIL 17, 2025

It reviews about half a dozen such studies, plus another ten looking at transdermal CBD for other conditions, including drug addiction, neurodegeneration, skin cancer, wound healing, and epilepsy. New clinical trials are urgently needed, they repeat in a familiar refrain. Scholfield, CN; Waranuch, N; Kongkaew, C.

Topical

LifeCannMD

JULY 31, 2025

Recent research from 2023 confirms what I see in my practice daily: medical cannabis often provides more comprehensive pain relief than opioids, addressing not just the physical sensation but the emotional toll that chronic pain takes. The beauty of CBD for epilepsy is that it rarely causes intoxication, even at higher doses.

Conditions

Project CBD

MARCH 21, 2023

Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.

Cannabinoids

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization

The Joint Blog

JANUARY 12, 2020

billion by 2023, according to the cannabis research firm Brightfield Group and noted by the AP. A small clinical trial at Colorado State University published in the Journal of the American Veterinary Medical Association in June found CBD oil reduced seizure frequency in 89 percent of the epileptic dogs that received it.

Pets

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation

Veriheal

NOVEMBER 7, 2024

Because the categorization of a controlled substance determines its availability and accessibility, the benefits of rescheduling are important to patients suffering from chronic pain, epilepsy, and other conditions. In August 2023, the HHS also crucially recommended to the DEA that cannabis be relisted from Schedule I to Schedule III.

DEA